Pharmacology of antidepressants

Slides:



Advertisements
Similar presentations
HuBio 543 September 6, 2007 Frank F. Vincenzi
Advertisements

Malignant Hypertension as a Presenting Symptom of Takayasu Arteritis Talya Wolak, MD, Gabriel Szendro, MD, Luis Golcman, MD, Esther Paran, MD Mayo Clinic.
Clinical Pharmacology, Uses, and Adverse Reactions of Iodinated Contrast Agents: A Primer for the Non-radiologist Jeffrey J. Pasternak, MD, Eric E. Williamson,
My Treatment Approach to Hairy Cell Leukemia Rahul R. Naik, MD, Alan Saven, MD Mayo Clinic Proceedings Volume 87, Issue 1, Pages (January 2012) DOI:
Diverticulosis and Diverticulitis
Managing Cancer Pain: Basic Principles and Invasive Treatments
Ductal Carcinoma in Situ of the Breast
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Amyotrophic Lateral Sclerosis: An Update for 2018
Evaluation of Proteinuria
Diverticulosis and Diverticulitis
Clopidogrel-Induced Systemic Inflammatory Response Syndrome
Robert M. Jacobson, MD, George J. Isham, MD, MS, Lila J
Sustained-Release Niacin for Prevention of Migraine Headache
Helicobacter pylori Mayo Clinic Proceedings
William L. Lanier, MD  Mayo Clinic Proceedings 
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Food Allergy: Common Causes, Diagnosis, and Treatment
Mechanisms of Drug-Induced Allergy
Peripheral Arterial Disease: Diagnosis and Management
Corticosteroids in the Treatment of Alcohol-Induced Rhabdomyolysis
George Dailey, MD  Mayo Clinic Proceedings 
Understanding Palliative Care and Hospice
Untitled by Martin Blank
Palliative Care and Hospice Programs
Topical Analgesics in the Management of Acute and Chronic Pain
Acupuncture Mayo Clinic Proceedings
Madonna della Pietá by Michelangelo
Antidepressant drugs.
Pancreatic Ductal Adenocarcinoma
Barbara P. Yawn, MD, MSc, MSPH, MeiLan K. Han, MD, MS 
Medical management of osteoarthritis
Ayalew Tefferi, MD  Mayo Clinic Proceedings 
Daniel M. Musher, MD  Mayo Clinic Proceedings 
Cardiac Production of Angiotensin II and Its Pharmacologic Inhibition: Effects on the Coronary Circulation  Axel Schmermund, M.D., Lilach O. Lerman, M.D.,
Treating Tobacco Dependence in Light of the 2008 US Department of Health and Human Services Clinical Practice Guideline  J. Taylor Hays, MD, Jon O. Ebbert,
Cocaine-Induced Pseudovasculitis
Refurbishing Mayo Clinic Proceedings:
Peripartum Cardiomyopathy Presenting as an Acute Myocardial Infarction
Internet Sex Addiction Treated With Naltrexone
Antidepressants and Brain Neurochemistry
Classic Hodgkin Lymphoma
Selective Estrogen Receptor Modulators and Phytoestrogens: New Therapies for the Postmenopausal Woman  Lorraine A. Fitzpatrick, MD  Mayo Clinic Proceedings 
Complex Regional Pain Syndrome
Evaluation and Management of Penicillin Allergy
Jöns Jacob Berzelius – A Father of Chemistry
Kenneth N. Huynh, BS, Ba D. Nguyen, MD  Mayo Clinic Proceedings 
Institutional Review Boards: What Clinician Researchers Need to Know
Diabetic Mastopathy Mayo Clinic Proceedings
Management Options for Irritable Bowel Syndrome
Hepatocellular Carcinoma
Methylphenidate: Its Pharmacology and Uses
Down River by Charles Munch
Pulmonary Tumor Embolism of Unknown Origin
Serial Measurement of Serum Tryptase in Angiotensin-Converting Enzyme Inhibitor- Associated Angioedema  Kevin R. Regner, MD, Douglas L. Riegert-Johnson,
Medical Treatment of Overactive Bladder: In Response
Lowering the High Cost of Cancer Drugs—IV
Ross Arena, PhD, PT, FAHA, Carl J. Lavie, MD  Mayo Clinic Proceedings 
Mantle Cell Involvement of the Spleen
Organic Causes of Mania
Squamous Cell Carcinoma of the Tongue
Preoperative Smoking Cessation: The Role of the Primary Care Provider
Medical Student Distress: Causes, Consequences, and Proposed Solutions
Clomiphene-Induced Severe Hypertriglyceridemia and Pancreatitis
21st Century Women's Health
Managing Cancer Pain: Basic Principles and Invasive Treatments
Diagnosis and Management of Headache in Older Adults
Mayo Clinic Proceedings 2012: “A New Era in Journal Stewardship”
Raphe Circuits on the Menu
16-Year-Old Boy With Gross Hematuria
Presentation transcript:

Pharmacology of antidepressants Elliott Richelson  Mayo Clinic Proceedings  Volume 76, Issue 5, Pages 511-527 (May 2001) DOI: 10.4065/76.5.511 Copyright © 2001 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 1 Some newer generation antidepressants. Mayo Clinic Proceedings 2001 76, 511-527DOI: (10.4065/76.5.511) Copyright © 2001 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 2 Elimination half-lives of antidepressants.36–43 Fluoxetine's active metabolite norfluoxetine has a half-life of 7 to 15 days.44 The shaded area highlights the half-life range for dosing once per day with immediate-release compounds to maintain good steady-state levels. Mayo Clinic Proceedings 2001 76, 511-527DOI: (10.4065/76.5.511) Copyright © 2001 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 3 Schematic of a raphe nucleus serotonergic neuron. Receptors are illustrated with 7 transmembrane-spanning segments. 5-HT = 5-hydroxytryptamine (adapted with permission from Briley and Moret76). Mayo Clinic Proceedings 2001 76, 511-527DOI: (10.4065/76.5.511) Copyright © 2001 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 4 Antidepressant inhibition of the human norepinephrine transporter. Potency (affinity) data are expressed as the inverse of the equilibrium dissociation constant Kd, multiplied by a factor of 10−7. The Kd is in molarity. Data derived from radioligand binding studies of the molecularly cloned human norepinephrine transporter.105 Mayo Clinic Proceedings 2001 76, 511-527DOI: (10.4065/76.5.511) Copyright © 2001 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 5 Antidepressant inhibition of the human serotonin transporter. Potency data are expressed as in the legend to Figure 4. Data from reference 105. Mayo Clinic Proceedings 2001 76, 511-527DOI: (10.4065/76.5.511) Copyright © 2001 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 6 Selectivity of antidepressants for blocking uptake of serotonin over norepinephrine. Data are ratios of numbers presented in Figures 4 and 5. Mayo Clinic Proceedings 2001 76, 511-527DOI: (10.4065/76.5.511) Copyright © 2001 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 7 Antidepressant inhibition of the human dopamine transporter. Potency data are expressed as in the legend to Figure 4. Methylphenidate is the reference compound. Data from reference 105. Mayo Clinic Proceedings 2001 76, 511-527DOI: (10.4065/76.5.511) Copyright © 2001 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 8 Antidepressant blockade of human a1-adrenoceptors. Affinity data are expressed as in the legend to Figure 4. Phentolamine is the reference compound. Data derived from radioligand binding studies of human brain tissue.108,109 Mayo Clinic Proceedings 2001 76, 511-527DOI: (10.4065/76.5.511) Copyright © 2001 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 9 Antidepressant blockade of human dopamine D2 receptors. Affinity data are expressed as in the legend to Figure 4. Chlorpromazine is the reference compound. Data from references 108 and 109. Mayo Clinic Proceedings 2001 76, 511-527DOI: (10.4065/76.5.511) Copyright © 2001 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 10 Antidepressant blockade of human histamine H1 receptors. Affinity data are expressed as in the legend to Figure 4. Diphenhydramine is the reference compound. Data from references 108 and 109. Mayo Clinic Proceedings 2001 76, 511-527DOI: (10.4065/76.5.511) Copyright © 2001 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 11 Antidepressant blockade of human muscarinic receptors. Affinity data are expressed as in the legend to Figure 4. Atropine is the reference compound. Data from references 108 and 109. Mayo Clinic Proceedings 2001 76, 511-527DOI: (10.4065/76.5.511) Copyright © 2001 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 12 Antidepressant blockade of human serotonin 5-hydroxytryptamine2A (5-HT2A) receptors. Affinity data are expressed as in the legend to Figure 4. Risperidone is the reference compound. Data from references 108, 109, and 120. Mayo Clinic Proceedings 2001 76, 511-527DOI: (10.4065/76.5.511) Copyright © 2001 Mayo Foundation for Medical Education and Research Terms and Conditions